Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 62

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 62
---
 transaction by Ms. Davis that was not filed until December 31, 2024, each due to administrative error. Additionally, Dr. Sidhu failed to timely file three Forms 4 for three transactions on an individual basis and seven Form 4s for seven transactions by JATT L.P., for which Dr. Sidhu is deemed to have shared beneficial ownership, each due to an administrative error. Mr. Badial failed to timely file three Forms 4 for three transactions due to an administrative error. Both individuals have since filed a Form 5 to disclose these transactions. 36 TABLE OF CONTENTS CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS Other than compensation and indemnification arrangements for our directors and executive officers, which are described elsewhere in this proxy statement, the following is a description of each transaction since January 1, 2023 and each currently proposed transaction in which: • JATT or Zura has been or is to be a participant; • the amounts involved exceeded or exceeds the lesser of (i) $120,000 or (ii) one percent of the average of our total assets on a consolidated basis at year end for the past two fiscal years; and • any of our directors, director nominees, executive officers or holders of more than five percent of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. 2023 Lilly License On April 26, 2023, our consolidated subsidiary ZB17 LLC (“ZB17”) entered into a license agreement (the “2023 Lilly License” and, together with the 2022 Lilly License (as defined below), the “Lilly Licenses”) with Lilly, for an exclusive license to develop, manufacture and commercialize a certain bispecific antibody relating to IL-17 and BAFF (“tibulizumab”) in exchange for an upfront payment consisting of $5.8 million as well as 1,000,000 Class A ordinary shares issued at a fair value of $7.84 per Class A Ordinary Share. During 2024, ZB17 made an additional payment of $5.0 million to Lilly in connection with the receipt of certain know-how, data, information and materials that Lilly is required to provide under the license agreement. As a finder’s fee for arranging the acquisition of the 2023 Lilly License, ZB17 granted Stone Peach the right, but not the obligation, to